<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03441516</url>
  </required_header>
  <id_info>
    <org_study_id>YMC034</org_study_id>
    <nct_id>NCT03441516</nct_id>
  </id_info>
  <brief_title>Effect of Choline Alphoscerate on Cognitive Function in Alzheimer's Dementia</brief_title>
  <acronym>ALFO-AD</acronym>
  <official_title>Effect of Choline Alphoscerate on Cognitive Function in Alzheimer's Dementia: A Multi-center, Randomized, Open-label, Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yuhan Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yuhan Corporation</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the performance of Alzheimer's Disease Assessment Scale-cognitive
      subscale (ADAS-cog) in patients with Alzheimer's disease (AD).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 19, 2018</start_date>
  <completion_date type="Anticipated">May 31, 2020</completion_date>
  <primary_completion_date type="Actual">July 4, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ADAS-cog</measure>
    <time_frame>At 24 weeks</time_frame>
    <description>To evaluate cognitive function</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ADAS-cog</measure>
    <time_frame>At 12 weeks</time_frame>
    <description>To evaluate cognitive function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>K-MMSE (Korean version of Mini-Mental State Examination)</measure>
    <time_frame>At 12 and 24 weeks</time_frame>
    <description>To evaluate cognitive function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FAB (Frontal Assessment Battery)</measure>
    <time_frame>At 12 and 24 weeks</time_frame>
    <description>To evaluate frontal lobe dysfunction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>S-IADL (Seoul-Instrumental Activities of Daily Living)</measure>
    <time_frame>At 12 and 24 weeks</time_frame>
    <description>To evaluate daily activities of living</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGA-NPI (Caregiver-Administered Neuropsychiatric Inventory)</measure>
    <time_frame>At 12 and 24 weeks</time_frame>
    <description>To evaluate neuropsychiatric symptom in dementia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in brain metabolism by F-18 FDG brain PET</measure>
    <time_frame>At 24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">79</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Alfoatirin® Tab. + Aripezil® Tab.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Choline Alphoscerate 400mg bid + Donepezil 10mg qd for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aripezil® Tab.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Donepezil 10mg qd for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alfoatirin® Tab. + Aripezil® Tab.</intervention_name>
    <description>Choline Alphoscerate 400 mg Oral Tablet bid + Donepezil 10 mg Oral Tablet qd for 24 weeks</description>
    <arm_group_label>Alfoatirin® Tab. + Aripezil® Tab.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aripezil® Tab.</intervention_name>
    <description>Donepezil 10 mg Oral Tablet qd for 24 weeks</description>
    <arm_group_label>Aripezil® Tab.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  50 - 90 years of age

          -  Clinical diagnosis of dementia of the Alzheimer type determined by Diagnostic and
             Statistical Manual of Mental Disorders (DSM-IV) criteria

          -  A diagnosis of probable Alzheimer's Disease, or mild to moderate AD determined by
             NIA-AA (National Institute on Aging and the Alzheimer's Association) criteria

          -  K-MMSE score of 12 - 26

          -  Global Clinical Dementia Rating (CDR) score of 0.5 - 2

          -  Patient taking 10 mg of donepezil per day for a minimum of 12 weeks with a stable
             dose, not taking other brain pills including choline alfoscerate for at least 2 weeks
             from screening. Drugs that are likely to affect cognition are permissible if the dose
             is regular and stable for at least 2 weeks before screening and if the treatment
             continues for the duration of the trial.

        Exclusion Criteria:

          -  Subject suspected of dementia due to organic causes other than Alzheimer's type
             dementia

          -  Other degenerative brain diseases or major mental illnesses such as major depression,
             bipolar disorder, alcohol/substance abuse or dependence, delirium

          -  Hypersensitive to choline alfoscerate, donepezil hydrochloride, or piperidine
             derivatives or the components of this drug

          -  Subject who has contraindications as listed in the SPC of choline alfoscerate or
             donepezil hydrochloride

          -  Other than the above who is deemed to be ineligible to participate in the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Dong-A University Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gyeongsang National University Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inje University Busan Paik Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inje University Haeundae Paik Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pusan National University Yangsan Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Changwon Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>February 5, 2018</study_first_submitted>
  <study_first_submitted_qc>February 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 22, 2018</study_first_posted>
  <last_update_submitted>October 21, 2019</last_update_submitted>
  <last_update_submitted_qc>October 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

